前列地尔对肝酶异常重症患者的疗效

Efficacy of alprostadil on critically ill patients with liver enzyme abnormalities

目的观察前列地尔对肝酶异常重症患者肝功能的影响。方法急诊ICU肝酶异常患者92例随机均分为两组:对照组予以原发病及保肝治疗;治疗组加用前列地尔10μg静脉泵入,每日2次,疗程为8d。比较两组疗效和不良反应。结果治疗后,两组肝酶指标ALT、AST、TBil和DBil均较治疗前好转(P<0.05),治疗组的改善更明显(P<0.05)。治疗组总有效率高于对照组(93.48%vs.76.09%)(P<0.05)。治疗组用药期间未出现前列地尔相关的不良反应。结论在常规治疗的基础上早期加用前列地尔能有效改善肝酶学异常重症患者的肝功能。

Objective To observe the effect of alprostadil on critically ill patients with liver enzyme abnormalities.Methods Ninety-two inpatients with liver enzymes abnormalities in EICU were equally and randomly divided into two groups.Group B received the basic treatments focused on primary disease and hepatoprotection.Group A was given additional intravenous infusion of alprostadil10μg twice a day for 8days.The efficacy and adverse effects were compared between two groups.Results The levels of ALT,AST,TBil and DBil in both groups were all improved after treatment compared to before（P〈0.05）,which were more obvious in group A than those in group B（P〈0.05）.The overall effectiveness rate in group A was higher than that in group B（93.48% vs.76.09%）（P〈0.05）.No alprostadil-related adverse effects were seen during treatment in group A.Conclusion On the basis of conventional therapy,earlier additional use alprostadil can effectively improve the liver functions in critically ill patients with liver enzyme abnormalities.